On June 20, 2017, Imagion Biosystems President and CEO Bob Proulx provided an update and briefing on the pending Imagion Biosystems initial public offering on the Australian Securities Exchange. An audio recording of the call is now available for listening:
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer